Clinical judgment in psychiatry. Requiem or reveille?

Nordic Journal of Psychiatry

Volumn 67, Issue 1, 2013, Pages 1-10

  Fava, Giovanni A ^a,b  

^a UNIVERSITY OF BOLOGNA   (Italy)

^b UNIVERSITY AT BUFFALO   (United States)

Author keywords

Clinical judgment; Clinimetrics; Conflict of interest; Evidence based medicine; Mental disorders

Indexed keywords

BENZODIAZEPINE DERIVATIVE;

BIPOLAR DISORDER; CLINICAL DECISION MAKING; CONFLICT OF INTEREST; EVIDENCE BASED MEDICINE; GENERALIZED ANXIETY DISORDER; INFORMATION RETRIEVAL; MEDLINE; MENTAL DISEASE; META ANALYSIS (TOPIC); METHODOLOGY; PSYCHIATRIST; PSYCHIATRY; PSYCHOPHARMACOTHERAPY; REVIEW; SCIENTIFIC LITERATURE; SYSTEMATIC REVIEW (TOPIC);

HUMANS; JUDGMENT; MENTAL DISORDERS; PSYCHIATRY; RESEARCH;

EID: 84873036707     PISSN: 08039488     EISSN: 15024725     Source Type: Journal    
DOI: 10.3109/08039488.2012.701665     Document Type: Review

References (107)

1. Engel GL. Physician scientists and scientific physicians. Am J Med 1987; 82: 107-11.
2. Fava GA. The intellectual crisis of psychiatric research. Psychother Psychosom 2006; 75: 202-8.
3. Feinstein AR. The intellectual crisis in clinical science. Persp Biol Med 1987; 30: 215-30.
4. Insel T, Cuthbert B, Gavery M, Heinssen R, Pine DS, Quinn K, Sanislow C, Wang P. Research Domain Criteria (RDoC): Toward a new classification framework for research on mental disorders. Am J Psychiatry 2010; 167: 748-51.
5. Fava GA. The clinical factor. Psychother Psychosom 2011; 80: 1-3.
6. Balon R. Clinical factor 2010. Psychother psychosom 2011; 80: 195-8.
7. Risch N, Herrell R, Lehner T, Liang KY, Eaves L, Hoh J, Griem A, Kovacs M, Ott J, Merikangas KR. Interaction between the serotonin transporter gene (5-HTTLPR), stressful life events, and risk of depression: A meta-analysis. JAMA 2009; 301: 2462-71.
8. Lipowski ZJ. Psychopathology as a science: Its scope and tasks. Comp Psychiatry 1966; 7: 175-82.
9. Faust D, Nurcombe B. Improving the accuracy of clinical judgment. Psychiatry 1989; 52: 197-208.
10. Fava GA. Unmasking special interest groups: The key to addressing conflict of interest in medicine. Psychother Psychosom 2010; 79: 203-7.
11. Maj M. Are psychiatrists an endangered species? World Psychiatry 2010; 9: 1-2.
12. Katschnig H. Are psychiatrists an endangered species? Observations on internal and external challenges to the profession. World Psychiatry 2010; 9: 21-8.
13. Chomsky N. Media control. The spectacular achievements of propaganda. New York: Seven Stories; 1997.
14. Feinstein AR. Meta-analysis: Statistical alchemy for the 21st century. J Clin Epidemiol 1995; 48: 71-9.
15. Tricco AC, Tetzlaff J, Moher D. The art and science of knowledge synthesis. J Clin Epidemiol 2011; 64: 11-20.
16. Fava GA. Meta-analyses and conflict of interest. C NS Dugs 2012; 26: 93-6.
17. Baldwin D, Woods R, Lawson R, Taylor D. Efficacy of drug treatments for generalised anxiety disorder: Systematic review and meta-analysis. BMJ 2011; 342: d1199.
18. Furukawa TA. Drug treatment for generalized anxiety disorder. BMJ 2011; 342: d1216.
19. Fava GA. Statistical alchemy for drug treatment of generalized anxiety disorder: A commentary on the meta-analysis by Baldwin et al. (BMJ 2011;342: d1199). Psychother Psychosom 2011; 80: 261-3.
20. Berney P, Halperin D, Tango R, Daeniker-Dayer I, Schulz P. A major change of prescribing pattern in absence of adequate evidence: Benzodiazepines versus newer antidepressants in anxiety disorders. Psychopharmacol Bull 2008; 41: 39-47.
21. Fava GA, Offidani E. The mechanisms of tolerance in antidepressant action. Progr Neuro-Psychopharmacol Biol Psychiatry 2011; 35: 1593-602.
22. Fava GA, Bernardi M, Tomba E, Rafanelli C. Effects of gradual discontinuation of selective serotonin reuptake inhibitors in panic disorder with agoraphobia. Int J Neuropsychopharmacol 2007; 10: 835-8.
23. Pereira TV, Ioannidis JPA. Statistically significant meta-analyses of clinical trials have modest credibility and inflated effects. J Clin Epidemiol 2011; 64: 1060-9.
24. Al Khalaf MH, Thalib L, Doi SAR. Combining heterogeneous studies using the random-effects model is a mistake and leads to inconclusive meta-analyses. J Clin Epidemiol 2011; 64: 119-23.
25. Moher D, Liberati A, Tetzlaff J, Altman DG, the Prisma Group. Preferred reporting items for systematic reviews and meta-analyses: The PRISMA statement. J Clin Epidemiol 2009; 62: 1006-12.
26. Fava GA, Kellner R. Prodromal symptoms in affective disorders. Am J Psychiatry 1991; 148: 823-30.
27. Molnar G, Feeney G, Fava GA. Duration and symptoms of bipolar prodromes. Am J Psychiatry 1988; 145: 1576-8.
28. Perry A, Tarrier N, Morriss R, McCarthy E, Limb K. Randomized controlled trial of efficacy of teaching patients with bipolar disorder to identify early symptoms of relapse and obtain treatment. BMJ 1999; 318: 149-53.
29. Tomba E, Fava GA. The sequential combination of pharmacotherapy and psychotherapy in mood disorders. J Contemp Psychotherapy 2009; 39: 101-9.
30. Fava GA. Subclinical symptoms in mood disorders: Pathophysiological and therapeutic implications. Psychol Med 1999; 29: 47-61.
31. Jackson A, Cavanagh J, Scott J. A systematic review of manic and depressive prodromes. J Affect Disorder 2003; 74: 209-17.
32. Skjelstad DV, Malt UF, Holte A. Symptoms and signs of the initial prodrome of bipolar disorder. A systematic review. J Affect Disord 2010; 126: 1-13.
33. Howes OD, Lim S, Theologos G, Yung AR, Goodwin GM, McGuire P. A comprehensive review and model of putative prodromal features of bipolar affective disorder. Psychol Med 2011; 41: 1567-77.
34. Laupacis A, Straus S. Systematic reviews. Time to address clinical and policy relevance as well as methodological rigor. Ann Intern Med 2007; 147: 273-5.
35. Fontanarosa PB, Flanagin A, de Angelis CD. Reporting conflict of interest, financial aspects of research, and role of the sponsors in funded studies. JAMA 2005; 294: 110-11.
36. Rothman DJ, McDonald WJ, Berkowitz CD, Chimonas SC, DeAngelis CD, Hale RW, Nissen SE, Osborn JE, Scully JH Jr, Thomson GE, Wofsy D. Professional medical associations and their relationships with industry. A proposal for controlling conflict of interest. JAMA 2009; 301: 1367-72.
37. Feinstein AR, Horwitz RI. Problems in the "evidence" of "evidencebased medicine". Am J Med 1997; 103: 529-35.
38. Glassman PA, Hunter Hayes J, Nakamura T. Pharmacological advertising revenue and physicians organizations: How much is too much? West J Med 1999; 171: 234-5.
39. Cosgrove L, Krimsky S, Vijayaraghavan M, Schneider L. Financial ties between DSM-IV panel members and the pharmaceutical industry. Psychother Psychosom 2006; 75: 154-60.
40. Cosgrove L, Bursztajn HJ, Krimsky S, Anaya M, Walker J. Conflicts of interest and disclosure in the American Psychiatric Association's Clinical Practice Guidelines. Psychother Psychosom. 2009; 78: 228-32.
41. Healy D. Irrational healers? Psychother Psychosom 2008; 77: 198-200.
42. Tomba E. Nowhere patients. Psychother Psychosom 2012; 81: 69-72.
43. Arfken CL, Balon R. Declining participation in research studies. Psychother Psychosom 2011; 80: 325-8.
44. Lewontin RC. Biology as ideology. New York: Harper and Collins; 1991.
45. Lipowski ZJ. Psychiatry: Mindless or brainless, both or neither? Can J Psychiatry 1989; 34: 249-54.
46. Kendler KS. Toward a philosophical structure for psychiatry. Am J Psychiatry 2005; 162: 433-40.
47. Van Praag HM. Over the mainstream: Diagnostic requirements for biological psychiatry research. Psychiatry Res 1997; 72: 201-12.
48. Belmaker RH. The future of depression psychopharmacology. CNS Spectr 2008; 13: 682-7.
49. Byrne SE, Rotschild AJ. Loss of antidepressant efficacy during maintenance therapy. J Clin Psychiatry 1998; 59: 279-88.
50. Paykel ES, Tanner J. Life events, depressive relapse and maintenance treatment. Psychol Med 1976; 6: 481-5.
51. Karlsson H, Hirvonen J, Kajander J, Markkula J, Rasi-Hakala H, Salminen JK, Nagren K, Aalto S, Hietala J. Psychotherapy increases brain serotonin 5-HT1A receptors in patients with major depressive disorder. Psychol Med 2010; 40: 523-8.
52. Feinstein AR. Clinical Judgment. Baltimore, MD: Williams & Wilkins; 1967.
53. Feinstein AR. The Jones criteria and the challenge of clinimetrics. Circulation 1982; 66: 1-5.
54. Feinstein AR. Clinimetrics. New Haven, CT: Yale University Press; 1987.
55. Fava GA, Tomba E, Sonino N. Clinimetrics: The science of clinical measurements. Int J Clin Practice 2012; 66: 11-15.
56. Fava GA, Rafanelli C, Tomba E. The clinical process in psychiatry: A clinimetric approach. J Clin Psychiatry 2012; 73: 177-184.
57. Tomba E, Fava GA. The emerging role of clinimetrics in psychological assessment. In Lange MA, editor, Leading-edge psychological tests and testing research. New York: Nova Science Publishing; 2007. p. 129-43.
58. Fava GA, Kellner R. Staging: A neglected dimension in psychiatric classification. Acta Psychiatr Scand 1993; 87: 225-30.
59. McGorry P, Hickie IB, Yung AR, Pantelis C, Jackson HJ. Clinical staging of psychiatric disorders. Aus N Zeal J Psychiatry 2006; 40: 612-22.
60. Bilsbury CD, Richman A. A staging approach to measuring patient-centred subjective outcomes. Acta Psychiatr Scand 2002; 106 Suppl 414): 5-40.
61. Andresen R, Caputi P, Oades L. Stages of recovery instrument. Aust N Zeal J Psychiatry 2006; 40: 972-80.
62. Fava GA, Grandi S, Zielezny M, Canestrari R, Morphy MA. Cognitive behavioral treatment of residual symptoms in primary major depressive disorder. Am J Psychiatry 1994; 151: 1295-99.
63. Fava GA, Rafanelli C, Grandi S, Conti S, Belluardo P. Prevention of recurrent depression with cognitive behavioral therapy. Arch Gen Psychiatry 1998; 55: 816-20.
64. Fava GA, Grandi S, Zielezny M, Rafanelli C, Canestrari R. Four year outcome for cognitive behavioral treatment of residual symptoms in major depression. Am J Psychiatry 1996; 153: 945-7.
65. Fava GA, Ruini C, Rafanelli C, Finos L, Conti S, Grandi S. Six-year outcome of cognitive behavior therapy for prevention of recurrent depression. Am J Psychiatry 2004; 161: 1872-6.
66. Tyrer P, Seivewright N, Ferguson B, Tyrer J. The general neurotic syndrome. Acta Psychiatr Scand 1992; 85: 201-6.
67. Slater E, Slater P. A heuristic theory of neuroses. J Neurol Psychiatry 1944; 7: 49-55.
68. Taylor GJ. Affects, trauma, and mechanisms of symptom formation. A tribute to John C. Nemiah, MD (1918-2009). Psychother Psychosom 2010; 79: 339-49.
69. Fava GA, Guidi J, Semprini F, Tomba E, Sonino N. Clinical assessment of allostatic load and clinimetric criteria. Psychother Psychosom 2010; 79: 280-3.
70. Lichtenberg P, Belmarker RH. Subtyping major depressive disorder. Psychother Psychosom 2010; 79: 131-5.
71. Bech P. The struggle for subtypes in primary and secondary depression and their mode-specific treatment or healing. Psychother Psychosom 2010; 79: 331-8.
72. Guidi J, Fava GA, Picardi A, Porcelli P, Bellomo, Grandi S, et al. Subtyping depression in the medically ill by cluster analysis. J Affect Disord 2011; 132: 383-8.
73. Hamilton M. Design of clinical trials and rating scale methods. In Paykel ES, Coppen A, editors. Psychopharmacology of affective disorders. Oxford: Oxford University Press; 1979. p. 221-34.
74. Guidi J, Fava GA, Bech P, Paykel E. The clinical interview for depression. Psychother Psychosom 2011; 80: 10-27.
75. Tomba E, Rafanelli C, Grandi S, Guidi J, Fava GA. Clinical configuration of cyclothymic disturbances. J Affect Disord 2012; 139: 244-249.
76. Fava GA, Rafanelli C, Tomba E, Guidi J, Grandi S. The sequential combination of cognitive behavioral treatment and well-being therapy in cyclothymic disorder. Psychother Psychosom 2011; 80: 136-43.
77. Fava GA. The decline of pharmaceutical psychiatry and the increasing role of psychological medicine. Psychother Psychosom 2009; 78: 220-7.
78. Pigott HE, Leventhal AM, Alter GS, Boren JJ. Efficacy and effectiveness of antidepressants: Current status of research. Psychother Psychosom 2010; 79: 267-79.
79. Simon GE, Von Korff M, Rutter CM, Peterson DA. Treatment process and outcomes for managed care patients receiving new antidepressant prescription for psychiatrists and primary care physicians. Arch Gen Psychiatry 2001; 58: 395-401.
80. American Psychiatric Association. Diagnostic and statistical manual of mental disorders (DSM-IV). Washington, D.C.: American Psychiatric Association; 1994.
81. Zimmerman M, Chelminski I, McDermut W. Major depressive disorder and Axis I diagnostic comorbidity. J Clin Psychiatry 2002; 63: 187-93.
82. Feinstein AR. The pre-therapeutic classification of comorbidity in chronic disease. J Chronic Dis 1970; 23: 455-68.
83. deGroot V, Beckerman H, Lankhorst GJ, Bouter LM. How to measure comorbidity: A critical review of available methods. J Clin Epidemiol 2003; 56: 221-9.
84. Emmelkamp PMG, Bouman TK, Scholing A. Anxiety disorders. Chichester: Wiley; 1993. p. 55-6.
85. Fava GA, Sonino N, Wise TN, editors. The psychosomatic assessment. Basel: Karger; 2012.
86. Cosci F, Fava GA. New clinical strategies of assessment of comorbidity associated with substance use disorders. Clin Psychol Rev 2011; 31: 418-27.
87. Feinstein AR. An analysis of diagnostic reasoning. I The domains and disorders of clinical macrobiology. Yale J Biol Med 1973; 46: 212-32.
88. Fava GA, Tomba E. New modalities of assessment and treatment planning in depression. CNS Drugs 2010; 24: 453-65.
89. Moncrieff J, Cohen D. Rethinking models of psychotropic drug action. Psychother Psychosom 2005; 74: 145-53.
90. Bhugra D, Easter A, Mallaris Y, Gupta S. Clinical decision making in psychiatry by psychiatrists. Acta Psychiatr Scand 2011; 124: 403-11.
91. Sirri L, Grandi S. Illness behavior. Adv Psychosom Med 2012; 32: 160-81.
92. Tomba E. Assessment of lifestyle in relation to health. Adv Psychosom Med 2012; 32: 72-96.
93. Ryff CD, Singer BH. Know thyself and become what you are: A eudaimonic approach to psychological well-being. J Happiness Stud 2008; 9: 13-39.
94. Bech P. Measuring psychological distress and well-being. Psychother Psychosom 1990; 54: 77-89.
95. Fava GA, Tomba E. Increasing psychological well-being and resilience by psychotherapeutic methods. J Personality 2009; 77: 1903-34.
96. Borm GF, Donders R. A treatment should be evaluated by small trials. J Clin Epidemiol 2009; 62: 887-9.
97. Jane-wit D, Horwitz RI, Concato J. Variation in results from randomized, controlled trials: Stochastic or systematic? J Clin Epidemiol 2010; 63: 56-63.
98. Horwitz RI, Singer BH, Makuch RW, Viscoli CM. Can treatment that is helpful on average be harmful to some patients? J Clin Epidemiol 1996; 49: 395-400.
99. Gardner DM, Baldessarini RJ, Waraich P. Modern antipsychotic drugs: A critical overview. CMAJ 2005; 172: 1703-11.
100. Cella M, Chalder T, White PD. Does the heterogeneity of chronic fatigue syndrome moderate the response to cognitive behavior therapy? An exploratory study. Psychother Psychosom 2011; 80: 353-8.
101. Schulz KF, Grines DA. Multiplicity in randomized trials II: Subgroup and interim analyses. Lancet 2005; 365: 1657-61.
102. Gail M, Simon R. Testing for qualitative interactions between treatment effects and patient subsets. Biometrics 1985; 41: 361-72.
103. Horwitz RI, Singer BH, Makuch RW, Viscoli CM. On reaching the tunnel at the end of the light. J Clin Epidemiol 1997; 50: 753-5.
104. Engel GL. From biomedical to biopsychosocial. Psychother Psychosom 1997; 66: 57-62.
105. Engel, G. L. How much longer must medicine's science be bound by a seventeenth century world view? Psychother Psychosom 1992; 57: 3-16.
106. Owens DK. Improving patient guidelines with patient-specific recommendations. Ann Intern Med 2011; 154: 638-9.
107. Tomba E, Fava GA. Treatment selection in depression: The role of clinical judgment. Psychiat Clin N Am 2012; 35: 87-98.